Research participants play a critical role in generating study results. The ACTIV-6 team of researchers, clinicians, and community partners appreciates the time and commitment of study participants and the role they play in helping to advance care for people with COVID-19.

Below we share results from the ivermectin 400 part of the study. These results do not impact participation in other parts of ACTIV-6 that continue to enroll participants. If you are currently taking part in the ACTIV-6 study, please continue taking the study medications and answering the surveys. We hope sharing these results will help participants understand and feel proud of the important part they play in ACTIV-6 and clinical research.

What is ivermectin 400?
Ivermectin is a medication introduced in 1971 as an animal de-wormer. It was approved for use in humans in 1986 to kill parasites that cause river blindness and other illnesses. In the ivermectin 400 part of the study, participants took a dose of 400 mcg/kg or a placebo every day for three days. A placebo looks the same as the study medication but does not include any active ingredients. Researchers then compared the results from people who took ivermectin with the results from people who took the placebo to see if there was any meaningful difference.

What were the study results for ivermectin?
Researchers found no benefit of taking ivermectin at this dose or length of time for the treatment of COVID-19. People who took ivermectin during the study did not have fewer hospital or emergency room visits compared to people who took the placebo.

Most people in the study felt better whether they took ivermectin or not. Ivermectin does not seem to be better than other options we already have for treating COVID-19.

There were no safety concerns with taking ivermectin at this dose for this length of time. This shows that ivermectin is safe to take as part of a clinical research study. ACTIV-6 will continue to study this medication at a higher dose (600 mcg/kg) and for a longer time period (six days).

This will help us learn whether giving ivermectin at a higher dose for a longer period of time will make enough of a difference to be considered a good option for treatment of COVID-19. We are committed to sharing results from the ivermectin 600 part of the study when they are available.

What is ACTIV-6?
ACTIV-6 is a platform trial, which means that it tests several different medications at the same time, instead of just one. All the medications tested in the study are safe and approved for different diseases and conditions. You can find out more about the medications being tested here.

When did this part of the study take place?
ACTIV-6 enrolled participants in the ivermectin 400 part of the study from June 2021 to February 2022. A total of 1,537 participants enrolled in this part of the study.

How will these results help people with COVID-19?
The results of this study may help people with mild-to-moderate COVID-19 feel better faster by providing at home treatment options that are already approved for other diseases and conditions.
Who is participating?
People who are 30 years old or older who have mild-to-moderate COVID-19 are taking part. ACTIV-6 has participants in every state in the U.S. and the District of Columbia.

Why is the ACTIV-6 study important?
Right now there are not many prescription medications that you can take easily at home to treat mild-to-moderate COVID-19.

The goal is to see if any already approved medications can help people with mild-to-moderate COVID-19 feel better faster and stay out of the hospital.

What happens during this study?

Learn about ACTIV-6 online, on the radio, or from health systems, pharmacies, testing centers, or community partners.

Test positive for COVID-19.

Enroll online or over the phone.

Receive assigned study medication and directions at home.

Take the study medication as directed.

Complete surveys about how you feel online or over the phone.

Share study findings with your family and healthcare provider.

Where can I learn more?
Visit the website at activ6study.org/study-results

@ACTIV6study

This summary was completed in June 2022. Other studies may find different results, and newer information may come out since this summary was written.

ACTIV-6 is part of the National Institutes of Health-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) and is led by the National Center for Advancing Translational Sciences (NCATS). The DCRI serves as the study’s clinical coordinating center, partnering with Vanderbilt University Medical Center as the study’s data coordinating center.